# 1 TITLE

2	Impact of SARS-CoV-2 Vaccines on Covid-19 Incidence and Mortality in the United States
3	
4	Fang Fang <sup>1</sup> , John David Clemens <sup>1,2,3</sup> , Zuo-Feng Zhang <sup>1,4,5</sup> , Timothy F. Brewer <sup>1,6</sup>
5	1. Department of Epidemiology, Fielding School of Public Health, University of California
6	at Los Angeles (UCLA), Los Angeles, CA, USA
7	2. International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh
8	3. International Vaccination Institute (IVI), Seoul, the Republic of Korea
9	4. Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA, USA
10	5. Center for Human Nutrition, Department of Medicine, UCLA David Geffen School of
11	Medicine, University of California at Los Angeles (UCLA), Los Angeles, CA, USA
12	6. Division of Infectious Diseases, UCLA David Geffen School of Medicine, Los Angeles,
13	CA, USA
14	Co-Correspondent Authors:
15	Timothy F. Brewer, MD, MPH
16	Professor of Epidemiology and Medicine
17	Division of Infectious Diseases
18	UCLA David Geffen School of Medicine
19	10833 Le Conte Ave
20	CHS 52-215
21	Los Angeles, CA 90095-1688

- 22 <u>TBrewer@mednet.ucla.edu</u>
- 23
- 24 Zuo-Feng Zhang, MD, PhD
- 25 Professor of Epidemiology and Medicine
- 26 UCLA Fielding Schools of Public Health and Medicine
- 27 650 Charles Young Drive, South
- 28 Los Angeles, CA 90095-1772
- 29 U.S.A.
- 30 zfzhang@ucla.edu
- 31

#### 32 ABSTRACT

Background: Despite safe and effective vaccines to prevent Severe Acute Respiratory
Syndrome coronavirus 2 (SARS-CoV-2) infections and disease, a substantial minority of the US
remains resistant to getting vaccinated. It is imperative to know if expanding vaccination rates
could reduce community-wide Coronavirus 2019 (COVID-19) disease, not just among those
vaccinated.

Methods: Negative binomial models were used to estimate associations between U.S. countylevel vaccination rates and county-wide COVID-19 incidence and mortality between April 23<sup>rd</sup> and September 30<sup>th</sup>, 2021. A two-week lag and a four-week lag were introduced to assess vaccination rate impact on incidence and mortality, respectively. Stratified analyses were performed for county vaccination rates >40%, and before and after Delta became the dominant variant.

Findings: Among 3,070 counties, each percentage increase in population vaccination rates 44 45 reduced county-wide COVID-19 incidence by 0.9% (relative risk (RR) 0. 9910 (95% CI: 0.9869, 46 0.9952)) and mortality by 1.9% (RR 0.9807 (95% CI: 0.9745, 0.9823)). Among counties with vaccination coverage >40%, each percentage increase in vaccination rates reduced COVID-19 47 disease by 1.5%, RR 0.9850 (95% CI: 0.9793, 0.9952) and mortality by 2.7% (RR 0.9727 (95% 48 CI: 0.9632, 0.9823)). These associations were not observed among counties with <40% 49 50 vaccination rates. Increasing vaccination rates from 40% to 80% would have reduced COVID-19 51 cases by 45.4% (RR 0.5458 (95% CI: 0.4335, 0.6873)) and deaths by 67.0% (RR 0.3305 (95% CI: 0.2230, 0.4898)). An estimated 5,989,952 COVID-19 cases could have been prevented and 52 53 127,596 lives saved had US population vaccination rates increased from 40% to 80%.

- 54 Interpretations: Increasing U.S. SARS-CoV-2 vaccination rates results in population-wide
- reductions in COVID-19 incidence and mortality. Furthermore, increasing vaccination rates
- above 40% has protective effects among non-vaccinated persons. Given ongoing vaccine
- 57 hesitancy in the U.S., increasing vaccination rates could better protect the entire community and
- 58 potentially reach herd immunity.
- 59 **Funding**: National Cancer Institute

### 60 **INTRODUCTION**

Since being recognized in December, 2019, the Severe Acute Respiratory Syndrome coronavirus 61 2 (SARS-CoV-2) pandemic has caused almost 250 million cases and five million deaths 62 worldwide.<sup>1</sup> The United States has been particularly affected, with more than 43 million 63 Coronavirus 2019 (COVID-19) cases and 697.000 deaths reported as of September 30<sup>th</sup>, 2021.<sup>2</sup> 64 65 Though a number of non-pharmacologic prevention initiatives (NPIs) have been introduced to slow SARS-CoV-2 transmission<sup>3</sup>, vaccines are now recognized as among the most effective 66 means for preventing COVID-19 cases and deaths.<sup>4</sup> 67 68 Three vaccine preparations are authorized for use in the US. The BNT162b2 vaccine (Pfizer, Inc. 69 and BioNTech), has full U.S. Food and Drug Administration (FDA) approval<sup>5</sup>, while mRNA-70 1273 (Moderna) and JNJ-78436735 (Janssen Pharmaceuticals) are available under an emergency 71 use authorization. All three vaccines are effective in preventing SARS-CoV-2 infections and 72 COVID-19 associated disease, hospitalizations, and deaths,<sup>6-8</sup> though vaccine effectiveness 73 wanes over time and breakthrough infections occur.<sup>4,9</sup> Vaccine effectiveness also varies by 74 SARS-CoV-2 variant, with higher rates of breakthrough infections or disease reported in 75 vaccinated persons infected with Delta or Beta compared with other variants.<sup>8,10</sup> With the 76 recognition of waning vaccine immunity and the rise of Delta as the predominant SARS-CoV-2 77 78 variant in the U.S., the FDA has authorized the emergency use of a booster for COVID-19

79 vaccines, including the use of a heterologous booster.<sup>11,12</sup>

81 Numerous studies have demonstrated that SARS-CoV-2 vaccines are effective in preventing 82 COVID-19 infections and disease in individuals outside of clinical trials, including among health 83 care workers, first responders, individuals attending ambulatory clinics, veterans, and in nursing homes.<sup>13-15</sup> Despite the proven safety and effectiveness of these vaccines, a substantial minority 84 of the adult US population remains resistant to getting vaccinated.<sup>16</sup> To understand if the SARS-85 CoV-2 pandemic can be stopped, it is imperative to understand the impact of vaccination on 86 87 community-wide SARS-CoV-2 cases and COVID-19 disease, not just among those vaccinated a concept popularly referred to as "herd immunity".<sup>17</sup> To investigate the impact of population 88 percentages of SARS-CoV-2 vaccination on community-wide COVID-19 case and mortality 89 rates, we undertook an ecological analysis of U.S. county vaccination rates on reported county 90 COVID-19 cases and deaths, controlling for socioeconomic, demographic, comorbid conditions, 91 92 rural/urban, air pollution, hospital capacity, and related factors, the introduction of NPIs and the 93 presence of Delta variant.

94

#### **METHODS** 95

Negative binomial models were used to estimate associations between U.S. county-level 96 vaccination rates and county-wide COVID-19 incidence and mortality between April 23<sup>rd</sup> and 97 September 30<sup>th</sup>, 2021. The dates represent when Delta was first recognized in the U.S. to the end 98 of the study period. To account for the rise of Delta as the dominant U.S. variant, additional 99 analyses were done dividing the study period into before (April  $23^{rd}$  – July  $2^{nd}$ ) and after (July 100  $3^{rd}$  – September 30<sup>th</sup>) Delta was responsible for the majority of reported U.S. COVID-19 cases. 101

103	Both models were adjusted for the following potential confounders: annual average of ambient
104	atmospheric particulate matter <2.5 $\mu m$ in diameter (PM_{2.5}) between 2000 and 2016, population
105	density, poverty, education, proportions of White, proportions of male, proportion of population
106	older than 65 years old, owner-occupied property, median house value, median household
107	income, percentage of people under 65 years old without health insurance, prevalence of tobacco
108	smoking, and obesity. All covariates were measured at the county level. State-level variables for
109	NPIs policies (facemask mandates, stay home orders) also were included in both models. The
110	mortality model additionally adjusted for the number of county hospital beds.
111	
112	County-level COVID-19 case and mortality data were obtained from the Johns Hopkins
113	University, Center for Systems Science and Engineering Coronavirus Resource Center (CSSE).
114	CSSE collects county-level confirmed numbers of cases and deaths of 3,342 counties across the
115	U.S. from the U.S. Centers for Disease Control and Prevention (CDC) as well as state
116	departments of health since January 21st, 2020. <sup>2</sup>
117	
118	County-level vaccine data were obtained from Covid Act Now. These data are derived from the
119	U.S. Department of Health and Human Services, the CDC, the New York Times, and official
120	state and county dashboards. Data on vaccinations initiated and vaccination regimens completed
121	were available for all 50 states. <sup>18</sup> To allow for the development of protective immunity after
122	vaccination, a two-week lag was introduced after people were completely vaccinated (a person
123	vaccinated on June 18th was considered fully protected by July 2nd). A two-week lag also was
124	used to account for time between exposure and development of COVID-19 disease. To assess the

125	impact of vaccination on COVID-19 mortality, a four-week lag was used (vaccinated by
126	September 2 <sup>nd</sup> to assess the impact on mortality on September 30 <sup>th</sup> ).

127

128 County-level annual average of PM<sub>2.5</sub> between the years 2000 and 2016, as well as county-level covariates, were available from a GitHub repository.<sup>19</sup> County-level socioeconomic and 129 demographic variables for 2018 were available from the US Census/American Community 130 131 Survey. 2020 data on the prevalence of adult tobacco smoking and adult obesity were accessible through the County Health Rankings & Roadmaps program.<sup>20</sup> The number of county hospital 132 beds were obtained from an ArcGIS Hub dataset.<sup>21</sup> State averages were used to replace missing 133 values for county-level prevalence for smoking, obesity, and numbers of hospital beds. U.S. 134 Department of Agriculture 2013 rural and urban codes<sup>22</sup> were used to identify whether a county 135 136 was located in metropolitan areas. State-wide non-pharmacologic prevention policies, including 137 facemask use and stay home orders, were obtained from the Boston University School of Public Health.<sup>23</sup> 138

139

Counties with invalid Federal Information Processing Standards (n = 10), missing covariates (n = 236), missing vaccination status on June 4<sup>th</sup> (n = 4), and negative change in incidence (n = 22) or in mortality (n = 61) possibly due to data entry error were excluded. As a result, data from 3,070 counties in 49 states were available to investigate the association between population vaccination rates and county-wide COVID-19 incidence and 3,031 counties in 49 states to investigate the association between vaccination rates and COVID-19 mortality (Table 1).

147	As the average US county total population complete vaccination rate at the time of analysis was
148	approximately 40%, further stratified analyses were performed investigating associations
149	between counties where >40% of the total population was completely vaccinated with those with
150	<40% complete population vaccination rates. The impact of 10% incremental increases in total
151	population vaccine coverage was assessed in sensitivity analyses. To account for the correlation
152	within each state, we applied the robust error estimation. <sup>24</sup> Relative risks (RR) and 95%
153	confidence intervals (CI) are reported. Analyses were performed in SAS 9.4 (Cary, NC). To
154	estimate the number of COVID-19 cases or deaths that could have been prevented during the
155	study period by increasing county-wide vaccination rates, RRs were multiplied by the total at-
156	risk US population. The at-risk population was estimated using the total 2021 U.S. population,
157	subtracting the number of reported COVID-19 cases and deaths when estimating the population
158	at risk for COVID-19 incidence and reported COVID-19 deaths only when estimating the
159	population at risk for COVID-19 mortality.

160

### 161 **RESULTS**

Among the 3,070 counties across 49 states, the average county total population complete vaccination rate was 42.3% as of September 16<sup>th</sup>, 2021. Counties with >40% complete vaccination rates had more hospital beds, higher median house values, higher median household incomes, higher population density, and less uninsured population compared with counties with <40% vaccination rates. These counties also were more likely to be located in metropolitan areas and in states where a facemask policy was ever issued before September 30<sup>th</sup>, 2021 (Table 2).

Overall, each percentage increase in a county's total population vaccination rate between April
 23<sup>rd</sup> and September 30<sup>th</sup>, 2021 was associated with a 0.9% reduction in county-wide COVID-19

171	cases (relative risk (RR) 0.9910 (95% CI: 0.9869, 0.9952)) and a 1.9% reduction in county-wide
172	COVID-19 mortality (RR 0.9807 (95% CI: 0.9745, 0.9823)). County population vaccination was
173	associated with greater protection against COVID-19 infection, RR of 0.9895 (95% CI: 0.9851,
174	0.9940), and mortality, RR 0.9742 (95% CI: 0.9670, 0.9804), when the analysis was limited to
175	July 3 <sup>rd</sup> to September 30 <sup>th</sup> , corresponding to when Delta became the predominant SARS-CoV-2
176	variant in the U.S. (Table 3).

177

Among the 1,686 counties in 49 states with complete vaccination coverage >40% as of 178 September 16<sup>th</sup>, each percentage increase in county complete vaccination rates reduced the 179 180 county population RR of COVID-19 disease by 1.5%, RR 0.9850 (95% CI: 0.9793, 0.9952). However, in counties with <40% complete vaccination rates, the association became null, RR 181 182 1.0021 (95% CI: 0.9957, 1.0084). In the 1,442 counties in 49 states with vaccination rate >40% as of September 2<sup>nd</sup>, each percentage increase in the vaccination rate reduced county-wide 183 COVID-19 mortality by 2.7% (RR 0.9727 (95% CI: 0.9632, 0.9823)). In contrast, increasing 184 185 vaccination rates were not associated with reductions in county-wide COVID-19 mortality among counties with <40% population vaccination rates (RR 0.9938 (95% CI: 0.9849, 1.0027)). 186 187 Similar results were observed before and after Delta became the most dominant U.S. variant, as well as when further stratifying by 10% incremental increases in vaccination rates (Table 3). 188 189 Compared to a county with 40% of its total population being completely vaccinated, increasing 190

the population vaccination rate to 80% would have reduced COVID-19 cases by 45.4% (RR

192 0.5458 (95% CI: 0.4335, 0.6873)) between April 23<sup>rd</sup> and September 30<sup>th</sup> and COVID-19 deaths

193 by 67.0% (RR 0.3305 (95% CI: 0.2230, 0.4898)). Given the at-risk US population, an estimated

5,989,952 COVID-19 cases could have been prevented and 127,596 lives saved had US
population vaccination rates increased from 40% to 80% (Table 4 and Table 5).

196

#### 197 **DISCUSSION**

198 Data from 3,070 counties across 49 states demonstrates that each percentage increase in people

being completely vaccinated was associated with a 0.9% decrease in population-wide COVID-19

cases and a 1.9% reduction in COVID-19 mortality between April 23<sup>rd</sup> and September 30<sup>th</sup>, 2021

after adjusting for potential confounders. Limiting the analysis to between July 3<sup>rd</sup> and

202 September 30<sup>th</sup>, when Delta was the predominant US variant, gave similar results; each

percentage increase in population vaccination rates was associated with a 1.1% decrease in

county-wide COVID-19 cases and a 2.6% reduction in COVID-19 deaths. Among the counties

with vaccination rate >40%, an additional percentage increase in vaccination rate was associated

with a 1.5% reduction in population COVID-19 cases and 2.7% decrease in COVID-19

207 mortality. In contrast, null associations were observed for counties with <40% coverage of

208 complete vaccination rates. If a county increased its complete vaccination coverage from <40%

to 80% during the study period, 45.4% infections and 67.0% deaths due to COVID-19 might

210 have been prevented.

211

This study is among the first to demonstrate the impact of increasing SARS-CoV-2 vaccination rates on population-wide reductions in COVID-19 incidence and mortality. As the percentage reductions in population COVID-19 cases and deaths generally exceeded the percentage increases in population vaccination rates, these data suggest that increasing population vaccination rates has spillover protective effects among non-vaccinated persons. Moreover, these

spillover protective effects grow as population vaccination rates rise. Given ongoing vaccine
hesitancy in the US, these results show how increasing vaccination rates could better protect the
entire community and potentially reach herd immunity.

220

We observed clear reductions in COVID-19 cases and deaths with rising population SARS-CoV-221 222 2 vaccination rates among counties with >40% vaccination coverage, but not among those with 223 <40% population vaccination rates. This observation was consistent with the Israeli study showing declined COVID-19 incidence as vaccination rates increased.<sup>25</sup> Similar results were 224 225 found in the stratified analyses of 10% incremental increases in vaccination rates. Though these 226 data do not enable us to determine the population vaccine rate necessary to achieve herd immunity, the results showed that at least a 40% population vaccine coverage rate is needed to 227 see a protective impact of vaccination among the entire population. 228

229

230 The study was subject to several limitations. First, ecologic study designs are vulnerable to the 231 ecologic fallacy. Therefore, caution is required when interpreting the study results, especially 232 when extrapolating population findings to the individual level. In addition, we cannot rule out the 233 possibility of residual confounding even after controlling for numerous county-level and statelevel covariates. Using COVID-19 reported cases may underestimate of the number of actual 234 235 infections due to under-testing of asymptomatic patients. However, alternative estimates for cumulative incidence, such as seroprevalence<sup>26</sup>, also have limitations including sampling bias, 236 test sensitivity and specificity, and the progress of the pandemic.<sup>27</sup> Our analysis was not able to 237 238 assess the impact of the three different vaccines currently available in the U.S., which likely had

239	different efficacies. Although a detailed distribution of different variants in the U.S. was not
240	available, we examined the associations before and after the Delta variant became the
241	predominant strain. Therefore, our results represent the associations between vaccine rates
242	overall and COVID-19 incidence and mortality in the U.S. for vaccines as actually deployed and
243	SARS-CoV-2 variants as they circulated during the period of our analysis.
244	
245	The differential impact of rising population vaccination rates between before and after the spread
246	of Delta variant might be due to the proportion of counties achieving >40% complete vaccination
247	coverage. Before July 3 <sup>rd</sup> , <30% of counties reached 40% population vaccination rates; almost
248	half of counties had >40% of their total population vaccinated by September 30 <sup>th</sup> , 2021. Finally,
249	there was limited power to assess impact in counties with vaccination rates <20% or >70%. As a
250	result, counties were combined into either < or >40%, the approximate U.S. county average, to
251	obtain sufficient power and to account for the heterogeneity.
252	
253	Nevertheless, this study is the first to estimate the association between complete vaccination

rates and COVID-19 incidence and mortality in the U.S. general population using county-level

data. This nation-wide study covers 3,070 counties in 49 states across the entire country,

showing the population-based impact of increasing complete vaccination rates. The proportion of

the Delta variant surpassed the proportion of the Alpha variant and accounted for >50% of

infection in the U.S. as of June 26<sup>th</sup>, 2021.<sup>12</sup> Our results indicated that increasing complete

vaccination rates were associated with reduced COVID-19 incidence and mortality overall and

after July 3<sup>rd</sup>, demonstrating the vaccine impact within communities against SARS-CoV-2

261 variants in the U.S. including the Delta variant. The population-wide protective associations 262 observed only among counties with >40% vaccination rates urge the uptake of vaccines in all 263 counties. Though we showed estimated COVID-19 incidence and mortality reductions with 264 complete vaccination rates increasing above 40%, these results should be interpreted with caution since there were limited data for counties with very high vaccination coverage rates. 265 Future research should examine the barriers to vaccine uptake, especially among under-266 267 privileged populations, as well as estimate the vaccination coverage needed to reach the herd 268 immunity.

269

## 270 **CONTRIBUTORS**

271 ZF Zhang conceptualized and supervised the project. ZF Zhang and F Fang developed the

272 methods. F Fang obtained the data, conducted the analysis and wrote the original draft. JD

273 Clemens, TF Brewer and ZF Zhang provided feedback on the analyses and edited the draft. All

authors reviewed and revised the manuscript for critical content.

275

# 276 **DECLARATION OF INTERESTS**

F Fang and TF Brewer held stock in Pfizer. All other authors declare no competing interests.

### 279 ACKNOWLEDGEMENTS

- 280 We acknowledged all organizations and groups collecting and maintaining the publicly available
- data sources listed in Table 1 and utilized in this study. F Fang is supported by the NIH/NCI T32
- 282 CA009142. The funding source did not involve in this study.

Sources	Description
Johns Hopkins University Center for Systems Science and Engineering Coronavirus Resource Center (CSSE) <sup>2</sup>	Cumulative county-level confirmed cases and deaths up to September 30, 2021
Covid Act Now <sup>18</sup>	Cumulative county-level number of people completely vaccinated up to September 16, 2021
GitHub repository <sup>19</sup>	Annual average $PM_{2.5}$ concentration between 2000 and 2016
The US Census/American Community Survey	County-level socioeconomic and demographic variables in 2018
The County Health Rankings & Roadmaps program <sup>20</sup>	Country-level behavioral variables in 2020
ArcGIS hub <sup>21</sup>	Numbers of hospital beds in each county
Economic Research Service <sup>22</sup>	Urban/rural code in 2013
Boston University of Public Health <sup>23</sup>	State-level policy of face masks mandates and stay home orders

### 284 Table 1. Summary of data sources

285

	Total	Vaccination rate <sup>3</sup>	Vaccination rate <sup>3</sup>
	(n = 3.070  in  49)	on $9/16 \le 40\%$	on 9/16 > 40%
	states)	(n = 1,384  in  39)	(n = 1,686 in 49)
		states)	states)
	Mean (SD)	Mean (SD)	Mean (SD)
Incidence of COVID-19 as of 9/30 (%) <sup>1</sup>	13.75 (3.84)	14.58 (3.94)	13.07 (3.63)
Incidence of COVID-19 as of $7/2$ (%) <sup>1</sup>	10.25 (3.09)	10.50 (3.14)	10.04 (3.04)
Mortality of COVID-19 as of $9/30(\%)^2$	0.24 (0.13)	0.27 (0.13)	0.22 (0.12)
Mortality of COVID-19 as of $7/2$ (%) <sup>2</sup>	0.21 (0.12)	0.22 (0.11)	0.19 (0.11)
Full vaccination rate as of $9/16 (\%)^3$	42.27 (10.59)	33.26 (5.28)	49.66 (7.74)
Full vaccination rate as of $9/2 (\%)^3$	40.60 (10.71)	31.56 (5.24)	48.01 (8.03)
Full vaccination rate as of $6/18 (\%)^3$	34.75 (10.24)	26.73 (5.30)	41.32 (8.48)
Full vaccination rate as of $6/4 (\%)^3$	32.95 (9.62)	25.55 (5.17)	39.03 (8.05)
Average ambient $PM_{2.5} (\mu g/m^3)^4$	8.41 (2.52)	8.30 (2.53)	8.51 (2.51)
Ever smokers (%)	17.45 (3.54)	18.35 (3.59)	16.71 (3.32)
Adult obesity (%)	32.88 (5.41)	33.89 (5.05)	32.05 (5.55)
Number of hospital beds	398.59 (1103.58)	175.30 (233.47)	581.89 (1448.76)
Population living in poverty (%)	15.63 (6.43)	16.97 (6.24)	14.53 (6.37)
Population density per square mile	267.33 (1817.39)	61.91 (171.05)	435.95 (2434.89)
Owner occupied properties (%)	71.60 (8.06)	72.61 (7.13)	70.77 (8.66)
Population 25 years old and older with less than high school education (%)	20.57 (6.09)	22.48 (5.94)	19.00 (5.75)
White Americans population (%)	83.51 (16.25)	84.43 (15.62)	82.75 (16.73)
African Americans population (%)	9.13 (14.57)	9.05 (13.95)	9.20 (15.07)
Hispanic population (%)	9.21 (13.76)	8.47 (12.08)	9.82 (14.97)
Median house value (×\$1,000)	145.80 (87.18)	114.56 (40.55)	171.45 (105.05)
Median household income (×\$1,000)	51.40 (13.56)	46.94 (9.94)	55.07 (14.97)
Population over 65 years old (%)	20.28 (4.81)	20.25 (4.48)	20.31 (5.08)
Male (%)	50.06 (2.14)	50.35 (2.44)	49.82 (1.82)
Uninsured population (%)	8.88 (3.97)	10.40 (3.97)	7.64 (3.52)
Metropolitan, n (%)			
Yes	1151 (37.49)	649 (31.43)	486 (55.16)
No	1919 (62.51)	1416 (68.57)	395 (44.84)
State stay-home order before 9/30, n (%)			
Ever issued	2709 (88.24)	1218 (88.01)	1491 (88.43)
Never issued	361 (11.76)	166 (11.99)	195 (11.57)
State facemask policy before 9/30, n (%)			
Ever issued	2297 (74.82)	867 (62.64)	1430 (84.82)
Never issued	773 (25.18)	517 (37.36)	256 (15.18)

#### Table 2. Characteristics of counties (n = 3,070) in 49 states by vaccination rate as of 9/16

<sup>1</sup>COVID-19 cases out of total population in each county

<sup>2</sup>COVID-19 deaths out of total population in each county

<sup>3</sup>Number of people fully vaccinated out of total population in each county

<sup>4</sup>Annual average of PM<sub>2.5</sub> between 2000 and 2016

	RR (95% CI with naïve standard error estimation)		
T · 1	(95% CI	with robust standard error est	imation)
(n = 3.070  in  49  states)	$4/23/2021 - 7/2/2021^3$	$7/3/2021 - 9/30/2021^4$	$4/23/2021 - 9/30/2021^4$
(	0.9960	0.9895	0.9910
Overall	(0.9935, 0.9986)	(0.9875, 0.9915)	(0.9892, 0.9929)
	(0.9877, 1.0044)	(0.9851, 0.9940)	(0.9869, 0.9952)
11 100/	0.9857	0.9836	0.9850
Above 40%	(0.9795, 0.9920)	(0.9805, 0.9867)	(0.9821, 0.9878)
	(0.9768, 0.9947)	(0.9771, 0.9901)	(0·9793, 0·9907) 0·9933
70% and above	NA	NA	$(0.9525 \ 1.0360)$
			(0.9506, 1.0380)
			0.9917
60% - 69%	NA	NA	$(0.9729 \ 1.0107)$
			(0.9706, 1.0131)
			0.9798
50% - 59%	NA	NA	$(0.9679 \ 0.9918)$
			$(0.9682 \ 0.9915)$
			0.9907
40% - 49%	NA	NA	$(0.9825 \ 0.999)$
			(0.9825, 0.999)
	0.9968	1.0015	1.0021
Below 40%	(0.9924, 1.0012)	(0.9963, 1.0068)	(0.9970, 1.0071)
	(0.9847, 1.0091)	(0.9951, 1.0080)	(0.9957, 1.0084)
			0.9976
30% - 39%	NA	NA	(0.9879, 1.0075)
			(0.9887, 1.0067)
			1.0268
20% - 29%	NA	NA	(1.0063, 1.0477)
			(1.0095, 1.0444)
			1.0199
Below 20%	NA	NA	(0.9580, 1.0858)
			(0.9622, 1.0809)
Mortality <sup>2</sup> (n = 3,031 in 49 states)	$4/23/2021 - 7/2/2021^5$	7/3/2021 - 9/30/20216	4/23/2021 - 9/30/20216
	0.9971	0.9742	0.9807
Overall	(0.9933, 1.0009)	(0.9706, 0.9779)	(0.9779, 0.9835)
	(0.9878, 1.0065)	(0.9670, 0.9815)	(0.9745, 0.9869)
Above $10\%$	0.9773	0.9685	0.9727
AUUVE 4070	(0.9651, 0.9897)	(0.9616, 0.9754)	(0.9679, 0.9775)
	(0.9613, 0.9936)	(0.9567, 0.9804)	(0.9632, 0.9823)
70% and above	NΔ	NΔ	1.0682
		11/1	(0.9594, 1.1894)

# Table 3. Adjusted RRs of COVID-19 incidence and mortality associated with additional people fully vaccinated per 100 population by vaccination rates

			(0.9882, 1.1547)
			1.0013
60% - 69%	NA	NA	(0.9676, 1.0362)
			(0.9675, 1.0363)
			0.9618
50% - 59%	NA	NA	(0.9434, 0.9806)
			(0.9440, 0.9800)
			0.9775
40% - 49%	NA	NA	(0.9634, 0.9917)
			(0.9612, 0.9940)
Dalow 400/	1.0050	0.9899	0.9938
Delow 40%	(0.9995, 1.0105)	(0.9820, 0.9978)	(0.9873, 1.0003)
	(0.9896, 1.0206)	(0.9792, 1.0007)	(0.9849, 1.0027)
			0.9849
30% - 39%	NA	NA	(0.9731, 0.9968)
			(0.9726, 0.9973)
			1.0189
20% - 29%	NA	NA	(0.9923, 1.0462)
			(0.9953, 1.0431)
			1.0947
Below 20%	NA	NA	(0.9843, 1.2174)
			(1.0388, 1.1536)

<sup>1</sup>Models adjust for annual PM<sub>2.5</sub> concentration between 2000 and 2016, percentage of adults smokers, percentage of obese adults, percentage of people living under poverty, population density, percentage of owner occupied properties, percentage of people with less than high school education, percentage of White population, median household income, median house value, percentage of population over 65 years old, percentage of male, percentage of population under 65 years old without an insurance, metropolitan status (yes/no), stay home orders before 9/30 (ever/never)

<sup>2</sup>Model 2 adjusts for all covariates in model 1 + number of hospital beds

<sup>3</sup>Percentage of fully vaccinated population as of 6/18/2021, 877 counties in 47 states with complete vaccination rate above 40% and 2,193 counties in 42 states with complete vaccination rate below 40%

<sup>4</sup>Percentage of fully vaccinated population as of 9/16/2021, 1,686 counties in 49 states with complete vaccination rate above 40% (1,032 counties in 43 states with vaccination rate between 40% and 49%, 471 counties in 46 states with vaccination rate between 50% and 59%, 149 counties in 32 states with vaccination rate between 60% and 69%, and 34 counties in 20 states with vaccination rate of 70% and above) and 1,384 counties in 39 states with complete vaccination rate below 40% (36 counties in 14 states with vaccination rate below 20%, 260 counties in 32 states with vaccination rate between 20% and 29%, and 1,088 counties in 39 states with vaccination rate between 30% and 39%)

<sup>5</sup>Percentage of fully vaccinated population as of 6/4/2021, 684 counties in 47 states with complete vaccination rate above 40% and 2,347 counties in 44 states with complete vaccination rate below 40%

<sup>6</sup>Percentage of fully vaccinated population as of 9/2/2021, 1,442 counties in 49 states with complete vaccination rate above 40% (906 counties in 43 states with vaccination rate between 40% and 49%, 395 counties in 45 states with vaccination rate between 50% and 59%, 131 counties in 31 states with vaccination rate between 60% and 69%, and 29 counties in 19 states with vaccination rate of 70% and above) and 1,589 counties in 44 states with complete vaccination rate below 40% (43 counties in 15 states with vaccination rate of below 20%, 394 counties in 33 states with vaccination rate between 20% and 29%, and 1,172 counties in 40 states with vaccination rate between 30% and 39%)

#### 291 Table 4. Estimated adjusted RRs, risk reductions of COVID-19 incidence and cases could have

been prevented associated with complete vaccination rates between April 23 and September 30,

293 **2021** 

	חם1	Casas man 100 000	
	KK (050/ CI with news	Cases per 100,000 $n = 2^{100}$	Cases could have been
	(95% CI with haive	population	prevented
	standard error	(95% CI with haive	(95% CI with haive
	estimation)	standard error	standard error
	(95% CI with robust	estimation)	estimation)
	standard error	(95% CI with robust	(95% CI with robust
	estimation)	standard error	standard error
<u> </u>		estimation)	estimation)
Counties with 40%			2
complete vaccination	1.0000	4568.96	0
rate			
Counties with 50%	0.8595	3927.02	1,852,902
complete vaccination	(0.8352, 0.8846)	(3816.00, 4041.70)	(1,521,886, 2,173,369)
rate (each 10%	(0.8114, 0.9105)	$(3707.25 \ 4160.04)$	(1.180.319, 2.487.241)
increase)	(*****************	(3707 23, 1100 01)	
Counties with 60%	0.7388	3375.55	3,444,684
complete vaccination	(0.6975, 0.7826)	(3186.85, 3575.67)	(2,867,053, 3,989,345)
rate (each 20%	(0.6584, 0.8290)	$(3008 \cdot 20, 3787 \cdot 67)$	(2,255,134,4,504,992)
Increase)		(,,	
Counties with 70%	0.6350	2901.29	4,813,590
complete vaccination	(0.5825, 0.6923)	(2661.42, 3163.09)	(4,057,922, 5,505,955)
rate (each 30%	(0.5343, 0.7548)	(2441.20, 3448.65)	(3,233,677, 6,141,613)
Increase)			
Counties with 80%	0.5458	2493.74	5,989,952
complete vaccination	(0.4865, 0.6124)	$(2222 \cdot 80, 2798 \cdot 03)$	(5,111,636, 6,771,995)
rate (each 40%	(0.4335, 0.6873)	(1980.64, 3140.25)	(4,123,862, 7,470,955)
increase)	()	( , ,	
Counties with 90%	0.4692	2143.76	7,000,146
complete vaccination	(0.4063, 0.5418)	(1856.37, 2475.46)	(6,042,703, 7,829,666)
rate (each 50%	(0.3518, 0.6258)	(1607.36, 2859.26)	(4,934,918, 8,548,408)
increase)	(0 00000, 0 0200)	(2007, 2007, 2007, 20)	(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,

<sup>1</sup>Percentage of fully vaccinated population as of 9/16/2021; Models adjust for annual PM<sub>2.5</sub> concentration between 2000 and 2016, percentage of adults smokers, percentage of obese adults, percentage of people living under poverty, population density, percentage of owner occupied properties, percentage of people with less than high school education, percentage of White population, median household income, median house value, percentage of population over 65 years old, percentage of male, percentage of population under 65 years old without an insurance, metropolitan status (yes/no), stay home orders before 9/30 (ever/never) and facemask mandate before 9/30 (ever/never) <sup>2</sup>The average incidence among counties with less than 40% complete vaccination rates <sup>3</sup>The at-risk population was estimated using the total 2021 U.S. population, subtracting the number of reported COVID-19 cases and the number of reported COVID-19 deaths

#### 295 Table 5. Estimated adjusted RRs, risk reductions of COVID-19 mortality and deaths could have

been prevented associated with complete vaccination rates between April 23 and September 30,
 2021

2021			
	RR <sup>1</sup> (95% CI with naïve standard error estimation) (95% CI with robust standard error estimation)	Deaths per 100,000 population <sup>2</sup> (95% CI with naïve standard error estimation) (95% CI with robust standard error estimation)	Deaths could have been prevented <sup>3</sup> (95% CI with naïve standard error estimation) (95% CI with robust standard error estimation)
Counties with 40% complete vaccination	1.0000	57.39	0
rate Counties with 50% complete vaccination rate (each 10%	0·7582 (0·7219, 0·7963) (0·6872, 0·8366)	43·51 (41·43, 45·70) (39·44, 48·01)	46,083 (38,822, 53,001) (31,141, 59,615)
Counties with 60% complete vaccination rate (each 20% increase)	0.5749 (0.5211, 0.6342) (0.4722, 0.6999)	32·99 (29·90, 36·40) (27·10, 40·17)	81,017 (69,716, 91,271) (57,194, 100,590)
Counties with 70% complete vaccination rate (each 30% increase)	0·4359 (0·3762, 0·5050) (0·3245, 0·5855)	25.02 (21.59, 28.98) (18.62, 33.60)	107,509 (94,339, 118,886) (78,997, 128,740)
Counties with 80% complete vaccination rate (each 40% increase)	0·3305 (0·2716, 0·4022) (0·2230, 0·4898)	18·97 (15·59, 23·08) (12·80, 28·11)	127,596 (113,931, 138,822) (97,236, 148,084)
Counties with 90% complete vaccination rate (each 50% increase)	0·2506 (0·1961, 0·3203) (0·1532, 0·4098)	14·38 (11·25, 18·38) (8·79, 23·52)	142,824 (129,540, 153,211) (112,483, 161,387)

<sup>1</sup>Percentage of fully vaccinated population as of 9/2/2021; Models adjust for annual PM<sub>2.5</sub> concentration between 2000 and 2016, percentage of adults smokers, percentage of obese adults, percentage of people living under poverty, population density, percentage of owner occupied properties, percentage of people with less than high school education, percentage of White population, median household income, median house value, percentage of population over 65 years old, percentage of male, percentage of population under 65 years old without an insurance, metropolitan status (yes/no), stay home orders before 9/30 (ever/never), facemask mandate before 9/30 (ever/never) and number of hospital beds

<sup>2</sup>The average mortality among counties with less than 40% complete vaccination rates <sup>3</sup>The at-risk population was estimated using the total 2021 U.S. population, subtracting the number of reported COVID-19 deaths

298

#### 300 **REFERENCE**

- 1. World Health Organization. COVID-19 Weekly Epidemiological Update. Geneva: World
- Health Organization, 2021.
- 2. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in
- 304 real time. *Lancet Infect Dis* 2020; **20**(5): 533-4.
- 305 3. Fang F, Mu L, Zhu Y, Rao J, Heymann J, Zhang Z-F. Long-Term Exposure to PM2.5,
- 306 Facemask Mandates, Stay Home Orders and COVID-19 Incidence in the United States.
- 307 International Journal of Environmental Research and Public Health 2021; **18**(12): 6274.
- 4. Thompson MG, Burgess JL, Naleway AL, et al. Prevention and Attenuation of Covid-19
- 309 with the BNT162b2 and mRNA-1273 Vaccines. *N Engl J Med* 2021; **385**(4): 320-9.
- 5. U.S. Food and Drug Administration. FDA Approves First COVID-19 Vaccine. August
- 311 23, 2021 2021. https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-
- 312 <u>19-vaccine</u> (accessed August 26, 2021 2021).
- 6. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA
- 314 Covid-19 Vaccine. *N Engl J Med* 2020; **383**(27): 2603-15.
- 315 7. Doria-Rose N, Suthar MS, Makowski M, et al. Antibody Persistence through 6 Months

after the Second Dose of mRNA-1273 Vaccine for Covid-19. *New England Journal of Medicine* 

- 317 2021.
- 8. Sadoff J, Gray G, Vandebosch A, et al. Safety and Efficacy of Single-Dose
- Ad26.COV2.S Vaccine against Covid-19. *N Engl J Med* 2021; **384**(23): 2187-201.
- 320 9. Keehner J, Horton LE, Pfeffer MA, et al. SARS-CoV-2 Infection after Vaccination in
- Health Care Workers in California. *N Engl J Med* 2021.

322	10.	Rosenberg ES, Holtgrave DR, Dorabawila V, et al. New COVID-19 Cases and
323	Hospitalizations Among Adults, by Vaccination Status - New York, May 3-July 25, 2021.	
324	MMWR Morb Mortal Wkly Rep 2021; 70(37): 1306-11.	
325	11.	U.S. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Takes
326	Additional Actions on the Use of a Booster Dose for COVID-19 Vaccines. Silver Spring, MD;	
327	2021.	
328	12.	Centers for Disease Control and Prevention. Variant Proportions. 2021.
329	https://covid.cdc.gov/covid-data-tracker/#variant-proportions (accessed July 3, 2021 2021).	
330	13.	Thompson MG, Stenehjem E, Grannis S, et al. Effectiveness of Covid-19 Vaccines in
331	Ambulatory and Inpatient Care Settings. N Engl J Med 2021; 385(15): 1355-71.	
332	14.	Butt AA, Omer SB, Yan P, Shaikh OS, Mayr FB. SARS-CoV-2 Vaccine Effectiveness in
333	a High-Risk National Population in a Real-World Setting. Ann Intern Med 2021.	
334	15.	Cabezas C, Coma E, Mora-Fernandez N, et al. Associations of BNT162b2 vaccination
335	with S	SARS-CoV-2 infection and hospital admission and death with covid-19 in nursing homes
336	and healthcare workers in Catalonia: prospective cohort study. Bmj 2021; 374: n1868.	
337	16.	Fisher KA, Bloomstone SJ, Walder J, Crawford S, Fouayzi H, Mazor KM. Attitudes
338	Toward a Potential SARS-CoV-2 Vaccine : A Survey of U.S. Adults. Ann Intern Med 2020;	
339	<b>173</b> (12): 964-73.	
340	17.	Anderson RM, Vegvari C, Truscott J, Collyer BS. Challenges in creating herd immunity
341	to SARS-CoV-2 infection by mass vaccination. Lancet 2020; <b>396</b> (10263): 1614-6.	
342	18.	Covid Act Now. Covid Act Now API. 2021 ed; 2021.

- 19. Wu X, Nethery RC, Sabath MB, Braun D, Dominici F. Air pollution and COVID-19
- 344 mortality in the United States: Strengths and limitations of an ecological regression analysis.
- 345 *Science Advances* 2020; **6**(45): eabd4049.
- 20. The County Health Rankings & Roadmaps program. Health Behaviors. 2020.
- 347 https://www.countyhealthrankings.org/explore-health-rankings/measures-data-sources/county-
- 348 <u>health-rankings-model/health-factors/health-behaviors</u>.
- 349 21. GeoPlatform ArcGIS Online. Hospitals. 2020.
- 350 <u>https://hub.arcgis.com/datasets/geoplatform::hospitals/about</u> (accessed July 3, 2021 2021).
- 22. Economic Research Service. Rural-Urban Continuum Codes. 2020.
- 352 <u>https://www.ers.usda.gov/data-products/rural-urban-continuum-codes/2021</u>).
- 23. Raifman J, Nocka K, Jones D, et al. COVID-19 US state policy database. 2020.
- 354 24. Gotway CA, Stroup WW. A Generalized Linear Model Approach to Spatial Data
- Analysis and Prediction. Journal of Agricultural, Biological, and Environmental Statistics 1997;

**2**(2): 157-78.

- 357 25. Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA
- 358 BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and
- deaths following a nationwide vaccination campaign in Israel: an observational study using
- 360 national surveillance data. *The Lancet* 2021; **397**(10287): 1819-29.
- 26. Byambasuren O, Dobler CC, Bell K, et al. Comparison of seroprevalence of SARS-CoV-
- 2 infections with cumulative and imputed COVID-19 cases: Systematic review. PLOS ONE
- 363 2021; **16**(4): e0248946.
- 27. Accorsi EK, Qiu X, Rumpler E, et al. How to detect and reduce potential sources of
- biases in studies of SARS-CoV-2 and COVID-19. *Eur J Epidemiol* 2021; **36**(2): 179-96.